GSK’s Blenrep faces setback as FDA cancer committee votes against approval
The negative vote for Blenrep comes just days before the 23 July PDUFA date.
Syngene Thematic ADC WP
GSK’s Blenrep US comeback hindered by eye safety concerns
Piramal Pharma announces $90m investment to expand US sites
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
Orion and Glykos extend ADC collaboration
NextCure and Simcere partner to develop SIM0505 for solid tumours
NICE approves GSK’s belantamab mafodotin for blood cancer
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
